Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 15/20 | 0.49 |
| ▸ | PPARA | Q07869 | 15/20 | 0.49 |
| ▸ | PPARG | P37231 | 11/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25160253 | 0.87 | PPARD (0.53) | PPARDPPARAPPARGMEN1NPC1 | |
| SCHEMBL25160796 | 0.85 | PPARD (0.53) | PPARDPPARAPPARGMEN1NPC1 | |
| SCHEMBL25160757 | 0.82 | PPARG (0.50) | PPARDPPARAPPARGMEN1NPC1 | |
| SCHEMBL9123305 | 0.78 | PPARD (0.38) | PPARDPPARAPPARG | |
| SCHEMBL20639883 | 0.75 | PPARD (0.41) | PPARDPPARAPPARGNPC1ALDH1A1 | |
| SCHEMBL9039853 | 0.75 | MAPT (0.55) | PPARDPPARAPPARGALDH1A1SMN1; SMN2 | |
| SCHEMBL9118588 | 0.75 | METAP2 (0.42) | PPARDPPARAALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL9384752 | 0.75 | MAPT (0.58) | PPARDPPARAPPARGALDH1A1RAB9A | |
| SCHEMBL20644484 | 0.74 | ALDH1A1 (0.48) | PPARDPPARAPPARGMEN1NPC1 | |
| SCHEMBL20644479 | 0.73 | DGAT1 (0.48) | PPARDPPARAPPARGMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3397629-B1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598 LTD (KY) | 2023-04-19 | — | — | EP | disclosed |
| US-10464922-B2 | Metalloenzyme inhibitor compounds | NQP 1598, LTD. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190016700-A1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598, LTD. (KY) | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016700-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | PPARD 2769/4885PPARA 3103/4885PPARG 2205/4885 |
| US-10464922-B2 | Metalloenzyme inhibitor compounds | MMEL1, GPX1, MPO | PPARD 2769/4885PPARA 3103/4885PPARG 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.